Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery Technology
Rapid Dose Therapeutics (RDTCF) and Aavishkar Oral Strips have filed two crucial patent applications for innovative nicotine delivery technology. The patents cover both dissolvable and non-dissolvable oral nicotine strips using RDT's QuickStrip™ platform. The dissolvable variant enables nicotine delivery in under 2 minutes, while the non-dissolvable version offers extended release in a slim format.
The international PCT applications filed with WIPO extend protection to 158 jurisdictions worldwide. This development follows a pre-commercialization agreement with a leading global tobacco company announced in January 2025. The technology aims to provide a safer alternative for the 1.3 billion global tobacco users, targeting the 60% of smokers wanting to quit.
Rapid Dose Therapeutics (RDTCF) e Aavishkar Oral Strips hanno depositato due importanti domande di brevetto per una tecnologia innovativa di somministrazione della nicotina. I brevetti riguardano sia strisce orali di nicotina solubili che non solubili, basate sulla piattaforma QuickStrip™ di RDT. La versione solubile consente la somministrazione di nicotina in meno di 2 minuti, mentre quella non solubile offre un rilascio prolungato in un formato sottile.
Le domande internazionali PCT presentate all'OMPI estendono la protezione a 158 giurisdizioni in tutto il mondo. Questo sviluppo segue un accordo di pre-commercializzazione con una importante azienda globale del settore tabacco annunciato a gennaio 2025. La tecnologia punta a offrire un'alternativa più sicura per i 1,3 miliardi di consumatori di tabacco nel mondo, rivolgendosi al 60% dei fumatori che desiderano smettere.
Rapid Dose Therapeutics (RDTCF) y Aavishkar Oral Strips han presentado dos solicitudes de patente clave para una tecnología innovadora de administración de nicotina. Las patentes abarcan tiras orales de nicotina tanto solubles como no solubles que utilizan la plataforma QuickStrip™ de RDT. La variante soluble permite la entrega de nicotina en menos de 2 minutos, mientras que la versión no soluble ofrece una liberación prolongada en un formato delgado.
Las solicitudes internacionales PCT presentadas ante la OMPI extienden la protección a 158 jurisdicciones en todo el mundo. Este avance sigue a un acuerdo de precomercialización con una importante empresa tabacalera global anunciado en enero de 2025. La tecnología busca ofrecer una alternativa más segura para los 1.3 mil millones de usuarios de tabaco en el mundo, enfocándose en el 60% de los fumadores que desean dejar de fumar.
Rapid Dose Therapeutics (RDTCF)와 Aavishkar Oral Strips는 혁신적인 니코틴 전달 기술에 대한 두 건의 중요한 특허 출원을 제출했습니다. 이 특허들은 RDT의 QuickStrip™ 플랫폼을 이용한 용해성 및 비용해성 구강 니코틴 스트립을 모두 포함합니다. 용해성 버전은 2분 이내에 니코틴 전달이 가능하며, 비용해성 버전은 슬림한 형태로 장시간 방출을 제공합니다.
WIPO에 제출된 국제 PCT 출원은 전 세계 158개 관할구역에 보호를 확장합니다. 이 개발은 2025년 1월에 발표된 글로벌 주요 담배 회사와의 사전 상업화 계약에 따른 것입니다. 이 기술은 13억 명의 전 세계 담배 사용자 중 금연을 원하는 60%의 흡연자를 대상으로 더 안전한 대안을 제공하는 것을 목표로 합니다.
Rapid Dose Therapeutics (RDTCF) et Aavishkar Oral Strips ont déposé deux demandes de brevet importantes pour une technologie innovante de délivrance de nicotine. Les brevets couvrent des bandes orales de nicotine solubles et non solubles utilisant la plateforme QuickStrip™ de RDT. La version soluble permet une délivrance de nicotine en moins de 2 minutes, tandis que la version non soluble offre une libération prolongée dans un format fin.
Les demandes internationales PCT déposées auprès de l'OMPI étendent la protection à 158 juridictions dans le monde. Ce développement fait suite à un accord de pré-commercialisation avec une grande entreprise mondiale du tabac annoncé en janvier 2025. La technologie vise à offrir une alternative plus sûre aux 1,3 milliard d'utilisateurs de tabac dans le monde, ciblant les 60 % de fumeurs souhaitant arrêter.
Rapid Dose Therapeutics (RDTCF) und Aavishkar Oral Strips haben zwei wichtige Patentanmeldungen für eine innovative Nikotinabgabetechnologie eingereicht. Die Patente umfassen sowohl lösliche als auch nicht lösliche orale Nikotinstreifen, die auf der QuickStrip™-Plattform von RDT basieren. Die lösliche Variante ermöglicht die Nikotinabgabe in unter 2 Minuten, während die nicht lösliche Version eine verlängerte Freisetzung in einem schlanken Format bietet.
Die internationalen PCT-Anmeldungen bei der WIPO erweitern den Schutz auf 158 Rechtsgebiete weltweit. Diese Entwicklung folgt auf eine Vorvermarktungsvereinbarung mit einem führenden globalen Tabakunternehmen, die im Januar 2025 bekannt gegeben wurde. Die Technologie zielt darauf ab, eine sicherere Alternative für die 1,3 Milliarden Tabakkonsumenten weltweit zu bieten und richtet sich an die 60 % der Raucher, die mit dem Rauchen aufhören möchten.
- Patent protection extended to 158 jurisdictions worldwide through WIPO filings
- Partnership with a leading global tobacco company for pre-commercialization development
- Technology delivers nicotine in under 2 minutes, faster than traditional methods
- Large market opportunity with 1.3 billion global tobacco users, 60% seeking to quit
- Product still requires regulatory approvals across multiple jurisdictions
- Clinical validation activities yet to be completed
- Faces competition from established nicotine replacement therapies
Burlington, Ontario--(Newsfile Corp. - May 26, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips-representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use.
While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy.
"These patent filings reflect a pivotal milestone in our commitment to reimagining nicotine consumption," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "By combining the convenience and familiarity of pouch formats with rapid action of our QuickStrip™ technology, we are delivering a discreet, fast-acting alternative for adult nicotine users looking to transition away from combustible tobacco and vaping."
Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip™ nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences.
A Global Opportunity to Support Smoking and Vaping Cessation
According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to
"Even a modest shift-just a small percentage of smokers transitioning to our QuickStrip nicotine products-could deliver a profound public health benefit," said Jason Lewis, Co-Developer and Senior Vice President of RDT. "We believe this innovative format will resonate with a growing global population of adult users seeking modern, smoke-free solutions that are fast-acting, easy to use and unobtrusive."
Building on Momentum: Partnership with Global Tobacco Leader
These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives.
"With the support of a global industry leader and the successful filing of these two key patents, we are strongly positioned to introduce our novel nicotine delivery solutions to regulated markets worldwide," added Mark Upsdell, CEO of Rapid Dose Therapeutics.
RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.
For further information and future updates, visit www.rapid-dose.com.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics is a Canadian biotechnology company specializing in innovative, proprietary drug delivery technologies. Its flagship product, QuickStrip™, is a fast-dissolving oral thin film designed to deliver active ingredients rapidly, efficiently, and with high bioavailability.
About Aavishkar Oral Strips Pvt. Ltd.
Based in India, Aavishkar Oral Strips is a research-driven pharmaceutical and wellness company specializing in oral thin film technologies. The company partners globally to bring advanced delivery systems to the nutraceutical, pharmaceutical, and tobacco-free nicotine sectors.
Media Contact:
Investor Relations
Mark Upsdell
Rapid Dose Therapeutics Corp.
investorrelations@rapid-dose.com
+1 (416) 477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, statements pertaining to the use of funds from the Financing and the anticipated closing of the Financing and Shares for Debt Transaction, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253446
FAQ
What patents did RDTCF file for nicotine delivery technology in May 2025?
How fast does RDTCF's QuickStrip nicotine delivery technology work?
Who is RDTCF partnering with for nicotine delivery technology development?
What is the market potential for RDTCF's nicotine delivery technology?
When will RDTCF's nicotine delivery products be available in the market?
